In summary, these data show that the percentage of Ki67 + CD8 + cells is usually at a baseline proliferation rate below 3% in healthy secondary lymphoid organs. This rate is often markedly higher in inflammatory and neoplastic diseases compared to normal tissues.

Apr 26, 2017 · To compare the phenotype of Ki-67+PD-1+ and Ki-67+PD-1 neg CD8 T cells induced by PD-1–targeted therapy in NSCLC patients, we analyzed Bcl-2, HLA-DR, and CD38 expression. Bcl-2 is an antiapoptotic protein, highly expressed on naïve and memory T cells, but down-regulated in effector cells.

Nov 22, 2024 · In TNBC, increased CD8+ density in the IZ stroma (HR: 0.19, p = 0.0119) and Ki67-entropy (HR: 3.31, p = 0.0250) were independent predictors of worse BCSS. Combining these independent indicators enhanced prognostic stratification in both BC subtypes.

This study discusses substantive advances in T cell proliferation analysis, with the aim to provoke a re-evaluation of the generally-held view that Ki-67 is a reliable proliferation marker per se, and to offer a more sensitive and effective method ...

Apr 1, 2019 · We found that the fold-change in the percentage of Ki-67 + cells among peripheral blood PD-1 + CD8 + T cells 7 days after the first dose, a marker we termed Ki-67 D7/D0, predicted tumor response and survival.

Apr 27, 2017 · CD8 T Cells That Proliferate After PD-1–Targeted Therapies Have an Activated Effector-Like Phenotype and Express PD-1. We next sought to characterize posttreatment Ki-67+ CD8 T cells in patients that demonstrated ≥1.5–fold increase in CD8 T-cell proliferation following treatment initiation (n = 20, immunologically re-

A higher proliferation rate, as suggested by a high Ki-67 index, indicates a higher number of CD3+, CD8+, and CD20+ TILs. The present study demonstrated high numbers of TILs, thus providing initial information on the immunity profile of canine STS.

2 days ago · In addition, we found that Ki-67 + T regs were decreased in Atf4-deficient resting T regs and that Bcl-2 interacting mediator of cell death (Bim) + T regs were increased in Atf4-deficient effector T regs ... In CD8 + T cells, ATF4 sustains their survival and antitumor response through an unknown mechanism .

Oct 30, 2024 · The expression of Ki-67 of PB-CD8 + T CM and T EM can serve as a predictive biomarker for the clinical benefit of pembrolizumab therapy. Our study suggests that analyzing antibody-bound T cells could be a novel approach to predict the clinical outcomes of PD-1 blockade therapy.

Notably, it is widely acknowledged that Ki-67 emerges as a clinically practical biomarker for proliferation assessment among many cancer types (8, 9). Ki67 is a macromolecular protein encoded by MKI67 gene and expressed in the nucleus, which is a common indicator for detecting cell proliferation activity ( 10 , 11 ).